Diet weight loss company Noom announced it is launching a new program dubbed the Noom Microdose GLP-1Rx Program, which will provide members with personalized microdoses of GLP-1 medication.
The program, which the company says will be paired with behavioral change and coaching, offers a lower dose of the weight loss medications than standard GLP-1s.
Plans, which include the prescribed medication and the GLP-1 Companion, start at $119, followed by $199 per month.
Members will also receive continuous monitoring and adjustments, as well as access to clinicians and refills, when clinically needed.
"I have been microdosing GLP-1s since October. At first, my doctor prescribed it to lower my A1C, but the effects on my health proved far more positive and profound, despite the small dose. That's what makes today's launch personal," Geoff Cook, CEO of Noom, said in a LinkedIn post.
"Noom defines a microdose of GLP-1 as a fraction – 25% or less – of the typically prescribed maintenance dose. By that definition, 70% of Noom members receiving microdoses of GLP-1 report no side effects."
Noom's other offerings include access to GLP-1s with a prescription, including Wegovy, Ozempic, Zepbound, Mounjaro and generic liraglutide. The company also offers Metformin with a prescription.
THE LARGER TREND
Other digital health companies that have added GLP-1 offerings to their weight loss programs include direct-to-consumer virtual care company Hims & Hers.
In April, pharma giant Novo Nordisk announced it was partnering with Hims & Hers to offer Americans access to a bundled offering that included the obesity drug Wegovy alongside a Hims & Hers membership.
Hims & Hers began offering Wegovy to cash-paying patients with a prescription shortly after the announcement was made.
Two months later, Novo Nordisk announced it was terminating its contract with Hims & Hers due to concerns about the company's "illegal mass compounding and deceptive marketing."
Novo Nordisk alleged that Hims & Hers Health is violating federal law by selling compounded versions of the drug at scale under the pretense of "personalization."
Novo Nordisk also accused Hims & Hers of using misleading marketing practices that, it says, put patient safety at risk.
"We are disappointed to see Novo Nordisk management misleading the public. In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients," Hims & Hers' CEO Andrew Dedum wrote in a statement posted on X.
"We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision-making of providers and limit patient choice."
Other companies in the space include food and nutrition tracking app MyFitnessPal, women's telehealth company Wisp and food as medicine platform Nourish.
Last year, MyFitnessPal announced the release of a set of tools and content to support members taking GLP-1 medications by helping them maintain proper nutrition and consistency while experiencing weight loss.
Wisp announced a strategic partnership with Nourish to allow Wisp patients to access nutrition counseling services via their health insurance or an exclusive self-pay rate.
Additionally, patients enrolled in Wisp's weight care program can merge medical weight loss treatments with nutrition counseling from Nourish. The program offers access to GLP-1 prescriptions, such as Wegovy.
